Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors

Clinical Cancer Research

Volumn 18, Issue 24, 2012, Pages 6648-6657

  Shao, Longjiang ^a   Tekedereli, Ibrahim ^b   Wang, Jianghua ^a   Yuca, Erkan ^b   Tsang, Susan ^a   Sood, Anil ^b   Lopez Berestein, Gabriel ^b   Ozpolat, Bulent ^b   Ittmann, Michael ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOMAL NANOVECTOR; MESSENGER RNA; NANOCARRIER; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG SPECIFICITY; FUSION GENE; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL GENE DELIVERY SYSTEM; MALE; MOUSE; NANOPHARMACEUTICS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RNA SPLICING; TMPRSS2 ERG FUSION GENE; TREATMENT OUTCOME; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIPOSOMES; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANS-ACTIVATORS; TRANSFECTION;

EID: 84871200741     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2715     Document Type: Article

References (30)

1. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8. (Pubitemid 41528150)
2. Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006;66:8347-51. (Pubitemid 44449142)
3. Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster CS, et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 2007;26:2667-73. (Pubitemid 46632014)
4. Soller MJ, Isaksson M, Elfving P, Soller W, Lundgren R, Panagopoulos I. Con firmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 2006;45:717-9. (Pubitemid 43727158)
5. Lin B, Ferguson C, White JT, Wang S, Vessella R, True LD, et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 1999;59:4180-4. (Pubitemid 29418721)
6. Liu W, Ewing CM, Chang BL, Li T, Sun J, Turner AR, et al. Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers. Genes Chromosomes Cancer 2007;46:972-80. (Pubitemid 47502837)
7. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009;41:524-6.
8. Wang J, Cai Y, Yu W, Ren C, Spencer DM, Ittmann M. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res 2008;68:8516-24.
9. Sun C, Dobi A, Mohamed A, Li H, ThangapazhamRL, Furusato B, et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 2008;27:5348-53.
10. Mohamed AA, Tan SH, Mikhalkevich N, Ponniah S, Vasioukhin V, Bieberich CJ, et al. Ets family protein, erg expression in developing and adult mouse tissues by a highly specific monoclonal antibody. J Cancer 2010;1:197-208.
11. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8. (Pubitemid 32494397)
12. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004;431:371-8. (Pubitemid 39265678)
13. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ. Potential therapeutic applications of autophagy. Nat Rev Drug Discov 2007;6:304-12. (Pubitemid 46505881)
14. Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005;65:6910-8. (Pubitemid 41060730)
15. Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006;12:4916-24. (Pubitemid 44338579)
16. Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun 2002;296:1000-4.
17. Grunweller A, Wyszko E, Bieber B, Jahnel R, Erdmann VA, Kurreck J. Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 20 -O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res 2003;31:3185-93. (Pubitemid 37441778)
18. Wang J, Yu W, Cai Y, Ren C, Ittmann MM. Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia 2008;10:847-56.
19. Tekedereli I, Alpay SN, Tavares CDJ, Cobanoglu ZE, Kaoud TS, Sahin I, et al. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PLoS One 2012;7:e41171.
20. Kwabi-Addo B, Wang J, Erdem H, Vaid A, Castro P, Ayala G, et al. The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res 2004;64:4728-35. (Pubitemid 38924514)
21. Wang J, Cai Y, Shao LJ, Siddiqui J, Palanisamy N, Li R, et al. Activation of NF-{kappa}B by TMPRSS2/ERG fusion isoforms through Toll-like r-4. Cancer Res 2011;71:1325-33.
22. Feng S, Shao L, Yu W, Gavine P, Ittmann M. Targeting fibroblast growth factor receptor signaling inhibits prostate cancer progression. Clin Cancer Res 2012;18:3880-8.
23. Suh J, Rabson AB. NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? J Cell Biochem 2004;91:100-17.
24. Kluza E, Yeo SY, Schmid S, van der Schaft DW, Boekhoven RW, Schiffelers RM, et al. Anti-tumor activity of liposomal glucocorticoids: the relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity. J Control Release 2011;151:10-7.
25. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008;10:177-88. (Pubitemid 351240884)
26. Mazar AP, Henkin J, Goldfarb RH. The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis 1999;3:15-32. (Pubitemid 129644777)
27. Kong D, Li Y,WangZ, Banerjee S, Sarkar FH. Inhibition of angiogenesis and invasion by 3,30 -diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 2007;67:3310-9. (Pubitemid 46724870)
28. Zhang J, Patel L, Pienta KJ. Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. Prog Mol Biol Transl Sci 2010;95:31-53.
29. Ozpolat B, Sood AK, Lopez-Berestein G. Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med 2010;267:44-53.
30. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 2011;11:59-67.